Clinical Trial Update: A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) [Phase 1, Phase 2]

View source ↗

Summary

A pediatric/young adult trial evaluating pembrolizumab with investigational agents for hematologic malignancies or solid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasm Metastasis | Phase 1, Phase 2 | Status: WITHDRAWN